pyrazines has been researched along with Carcinoid Tumor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendell, J; de Haan, H; Filvaroff, EH; Hege, K; Li, S; Mahipal, A; Meyer, T; Mita, A; Mita, M; Munster, PN; Nemunaitis, J; Paz-Ares, L; Wolin, E | 1 |
| Chen, JX; Shen, L; Tu, DY; Wu, D; Ying, XD; Zhuang, YC | 1 |
| Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M | 1 |
| Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D | 1 |
2 trial(s) available for pyrazines and Carcinoid Tumor
| Article | Year |
|---|---|
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Topics: Administration, Oral; Adult; Aged; Carcinoid Tumor; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Neuroendocrine Tumors; Pyrazines | 2019 |
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2004 |
2 other study(ies) available for pyrazines and Carcinoid Tumor
| Article | Year |
|---|---|
Tetraphenylpyrazine-Based Luminescent Metal-Organic Framework for Chemical Sensing of Carcinoids Biomarkers.
Topics: Biomarkers, Tumor; Carcinoid Tumor; Humans; Hydroxyindoleacetic Acid; Luminescence; Luminescent Agents; Luminescent Measurements; Metal-Organic Frameworks; Molecular Structure; Particle Size; Pyrazines; Serotonin; Surface Properties; Zinc | 2021 |
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines | 2010 |